Does Rallies show 13F holders for CLDI?

Yes. Rallies tracks hedge fund and 13F ownership data for CLDI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CLDI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.

CLDI (Calidi Biotherapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Calidi Biotherapeutics, Inc. (CLDI) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDI trades at $0.17 with a market cap of $2.79M and a P/E ratio of -0.03. CLDI moved -8.04% today. Year to date, CLDI is -85.53%; over the trailing twelve months it is -96.84%. Its 52-week range spans $0.16 to $46.68. Rallies surfaces CLDI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CLDI stock?

Hedge funds tracked by Rallies that own CLDI include Highbridge Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Calidi Biotherapeutics, Inc..

CLDI Key Metrics

Key financial metrics for CLDI
Metric	Value
Price	$0.17
Market Cap	$2.79M
P/E Ratio	-0.03
EPS	$-5.95
Dividend Yield	0.00%
52-Week High	$46.68
52-Week Low	$0.16
Volume	342.78K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-20.06M
Gross Margin	0.00%

Top Hedge Funds Holding CLDI

Highbridge Capital holds 1.04K shares of CLDI, changed +0.00% as of Dec 31, 2025.

Latest CLDI News

Calidi Biotherapeutics Narrows Q1 Net Loss to $4.4M, Raises Cash to $6.6M and Secures AI Partnership — May 14, 2026
Calidi to Unveil CLD-401 IL-15 Virotherapy Data, Aims for IND Filing by Year-End — May 13, 2026
Calidi Biotherapeutics Taps TransferAI’s Sofie AI to Accelerate CLD-401 IND Filing by Year-End — Apr 29, 2026
Calidi Reveals CLD-401 Tumor-Targeted IL-15 Superagonist Data, Plans IND by Year-End — Apr 21, 2026
Calidi to Present RedTail Preclinical EEV Data, Plans IND Filing for CLD-401 — Apr 14, 2026

Recent CLDI Insider Trades

Camaisa Allan sold 850 (~$1.24K) on Dec 12, 2025.
Schoeneck James A bought 75.00K (~$150.00K) on Aug 21, 2025.
Poma Eric E bought 25.00K (~$50.00K) on Aug 21, 2025.

CLDI Analyst Consensus

CLDI analyst coverage data. Average price target: $0.00.

Common questions about CLDI

Who owns CLDI stock?: Hedge funds tracked by Rallies that own CLDI include Highbridge Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Calidi Biotherapeutics, Inc..
Does Rallies show 13F holders for CLDI?: Yes. Rallies tracks hedge fund and 13F ownership data for CLDI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CLDI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.